# OnCo record guardant360-cdx (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/guardant360-cdx/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "guardant360-cdx" ;
  schema:name "Guardant360 CDx"@en ;
  schema:description "A blood test that reads a tumour's mutations without a tissue biopsy and is the FDA-approved gateway to several targeted drugs."@en ;
  schema:url <https://onco.cc/drugs/guardant360-cdx/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P200010> ;
  onco:status "approved" ;
  onco:tag "test" ;
  onco:modality "Liquid biopsy companion diagnostic test (NGS, cfDNA)" ;
  schema:alternateName "Guardant360 CDx" ;
  onco:approval "US 2020: Companion diagnostic for osimertinib (EGFR) in NSCLC; first liquid comprehensive genomic profiling test", "US 2021: Companion claims for sotorasib (KRAS G12C) and amivantamab (EGFR exon 20 insertion)", "US 2023: Companion diagnostic for elacestrant (ESR1 mutation) in ER+/HER2- advanced breast cancer" ;
  onco:related <https://onco.cc/drugs/foundationone-cdx/>, <https://onco.cc/drugs/cobas-egfr-mutation-test/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/breast-hr-positive/>, <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/egfr/>, <https://onco.cc/targets/kras/>, <https://onco.cc/targets/estrogen-receptor/>, <https://onco.cc/targets/met/>, <https://onco.cc/targets/alk/>, <https://onco.cc/targets/ret/>, <https://onco.cc/targets/braf/> ;
  onco:drugs <https://onco.cc/drugs/osimertinib/>, <https://onco.cc/drugs/sotorasib/>, <https://onco.cc/drugs/amivantamab/>, <https://onco.cc/drugs/elacestrant/> ;
  onco:companies <https://onco.cc/companies/guardant-health/> ;
  onco:terms <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/companion-diagnostic-term/>, <https://onco.cc/terms/esr1-mutation/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-diaz-molecular-evolution-egfr-resistance-colorectal-nature-2012/>, <https://onco.cc/key-papers/paper-nakamura-triumph-ctdna-pertuzumab-trastuzumab-her2-colorectal-nat-med-2021/> .